Abstract
Purpose
The primary objective of this sub-study, undertaken as an extension to the previously reported phase-I study, was to explore the feasibility, tolerability and pharmacokinetics (PK) of belinostat when administered by the oral route. Preliminary pharmacodynamic (PD) studies were also performed to enable comparison of the biological effects of the oral and intravenous formulations.
Patients and methods
Oral belinostat was administered in a range of doses and schedules (once, twice or thrice daily), on either day 1 or days 1–5, of the second or a subsequent treatment cycle in 15 patients who were included in the phase-I trial of intravenous belinostat. Serial blood samples were collected for PK and PD (histone acetylation) analyses, and the results compared with corresponding analyses following intravenous administration.
Results
A total mean daily AUC of 2,767 ± 1,453 ng h/ml (8.7 ± 4.6 μM h) resulted from a dose of 1,000 mg/m2 once daily (qd). There was no clear evidence of drug accumulation on twice daily dosing (bid); however, a trend towards accumulation was apparent when belinostat was given three times daily (tid). Mean half-life (T½) of a single dose of 1,000 mg/m2 was 1.5 h (±0.3 h) and peak levels were reached in an average of 1.9 h (±0.3 h). The half-life was found to be independent of dose, but a trend towards increasing half-life following multiple dosing was observed. Histone H4 hyperacetylation in PBMCs estimated after oral dosing was comparable to that achieved after intravenous administration.
Conclusions
High doses of oral belinostat, up to 1,000 mg/m2 bid for 5 consecutive days, have been tolerated in this small study. An oral formulation could lead to enhanced drug exposure and, more importantly, prolonged effects on the intended drug target. Future trials are required to establish the optimal dose and schedule of oral administration of belinostat.
Similar content being viewed by others
References
Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210–1216
Van Lint C, Emiliani S, Verdin E (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Express 5:245–253
Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595–606
Chan HM, Krstic-Demonacos M, Smith L et al (2001) Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3:667–674
Plumb JA, Finn PW, Williams RJ et al (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2:721–728
Steele NL, Plumb JA, Vidal L et al (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14:804–810
Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174–17179
Tumber A, Collins LS, Petersen KD et al (2007) The histone deacetylase inhibitor PXD101 synergises with 5-Fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 60:275–283
Qian X, LaRochelle WJ, Ara G et al (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5:2086–2095
Qian X, Ara G, Mills E et al (2008) Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 122:1400–1410
Siu LL, Pili R, Duran I et al (2008) Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008:1940–1947
Ryan QC, Headlee D, Acharya M et al (2005) Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23:3912–3922
Kelly WK, O’Connor OA, Krug LM et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923–3931
Rubin EH, Agrawal NG, Friedman EJ et al (2006) A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 12:7039–7045
Acharya MR, Karp JE, Sausville EA et al (2006) Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 24:367–375
Acknowledgments
This study was supported by Topotarget, Copenhagen, Denmark. The investigators at both the study centres are supported by Cancer Research UK. The investigators are grateful to the research teams at both study centres for their support of this study and to the patients who agreed to participate in this study.
Author information
Authors and Affiliations
Corresponding author
Additional information
N. L. Steele and J. A. Plumb contributed equally to this work.
Rights and permissions
About this article
Cite this article
Steele, N.L., Plumb, J.A., Vidal, L. et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol 67, 1273–1279 (2011). https://doi.org/10.1007/s00280-010-1419-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-010-1419-5